Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor

Documenti analoghi

• Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
  di: Naveen Pemmaraju, et al.
  Pubblicazione: (2012-07-01)
• The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis
  di: Mahran Shoukier, et al.
  Pubblicazione: (2020-09-01)
• Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia
  di: Aziz Nazha, et al.
  Pubblicazione: (2012-08-01)
• Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
  di: David Sanford, et al.
  Pubblicazione: (2015-12-01)
• A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors
  di: Alejandro Zulbaran‐Rojas, et al.
  Pubblicazione: (2018-11-01)